Raxatrigine (also known as GSK-1014802 and CNV-1014802) is a novel, potent small molecule state-dependent sodium channel blocker, the Nav1.7 sodium channel inhibitor. It has the potential to be used as an analgesic and is being developed by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN).

纯度：≥98%

CAS：934240-31-0